Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Baker Flechtner

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Virology|February 21, 2016
Evolution of rational vaccine designs for genital herpes immunotherapyJohanna Katharina Kaufmann, Jessica Baker Flechtner
Vaccine|June 29, 2013
Proteins as T cell antigens: methods for high-throughput identificationDaniel Grubaugh, Jessica Baker Flechtner, Darren E Higgins
Vaccine|June 12, 2012
High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challengeMichele D Picard, Kenya Prince Cohane, Todd M Gierahn, et al.
Cell Host & Microbe|February 16, 2011
T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonizationKristin L Moffitt, Todd M Gierahn, Ying-jie Lu, et al.
Vaccine|September 20, 2016
Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trialJessica Baker Flechtner, Deborah Long, Shane Larson, et al.
Infection and Immunity|March 12, 2014
Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteinsKristin Moffitt, Mojca Skoberne, Angela Howard, et al.
Clinical and Vaccine Immunology : CVI|October 9, 2015
Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response ProfileMichele D Picard, Jean-Luc Bodmer, Todd M Gierahn, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Virology|February 21, 2016
Evolution of rational vaccine designs for genital herpes immunotherapyJohanna Katharina Kaufmann, Jessica Baker Flechtner
Vaccine|June 29, 2013
Proteins as T cell antigens: methods for high-throughput identificationDaniel Grubaugh, Jessica Baker Flechtner, Darren E Higgins
Vaccine|June 12, 2012
High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challengeMichele D Picard, Kenya Prince Cohane, Todd M Gierahn, et al.
Cell Host & Microbe|February 16, 2011
T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonizationKristin L Moffitt, Todd M Gierahn, Ying-jie Lu, et al.
Vaccine|September 20, 2016
Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trialJessica Baker Flechtner, Deborah Long, Shane Larson, et al.
Infection and Immunity|March 12, 2014
Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteinsKristin Moffitt, Mojca Skoberne, Angela Howard, et al.
Clinical and Vaccine Immunology : CVI|October 9, 2015
Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response ProfileMichele D Picard, Jean-Luc Bodmer, Todd M Gierahn, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Pageof 1